February 22, 2010
|Drugs into bodies ... not as clearcut as it sounds.|
Lipodystrophy is a condition resulting from the effects of certain medications, or even HIV itself, on how the body metabolizes and stores lipids (fat) in the body and in the bloodstream. Lipodystrophy causes wasting such as "sunken cheeks" -- facial lipoatrophy -- or the redistribution of body fat such as "truncal obesity" -- belly fat.
"This drug was tested on people with AIDS, so people with AIDS should have the ability to use and afford this drug," said Ken Fornataro, E-Access to Care Director of Housing Works. Fornataro and some advocates are skeptical about the emphasis being placed on this drug. A patient assistance program is expected, but details have not yet emerged.
Tesamorelin wasn't developed because people with HIV/AIDS saw a need. Theratechnologies, the biocompany that developed this weight-loss technology, viewed this as a strategy to get it to market quickly. "We are a small company, and we wanted something that had a manageable clinical program," said Andrea Gilpin, Theratechnologies Vice President of Investor Relations.
The FDA is expected to approve this drug only for use by people living with HIV/AIDS, although Gilpin said Theratechnologies is in the process of testing the drug for use of people with Growth hormone deficient abdominal obesity and diabetes. Still, off-label use for those looking for an anti-aging effect could be significant.
There are no drugs on the market specifically to fight lipodystrophy. Tim Horn, the editor of AIDSMeds.com who has been following the drug since its inception, said, it's hard to determine how well tesamorelin works against other agents, purely experimental or otherwise, without head-to-head studies.Tesamorelin trials show patients receive a reduction in fat deep within the belly by 15 to 18 percent.
"We know that Serostim ( a growth hormone) reduced VAT by around 21 to 24 percent in clinical trials, compared with tesamorelin's average 15 to 18 percent reduction in its own studies. Though Serostim may be more effective, tesamorelin's moderate efficacy and good safety profile is notable," Horn said.
Still, some are skeptical of the drug's importance. Jeff Taylor, a patient advocate on AIDS Treatment Activists Coalition's (ATAC) drug development committee was a trial participant in the drug development, and said "it's an okay drug." I've been on the drug for wasting before. Tesamorelin took longer and the results weren't better. It wouldn't be the complete answer to the problem," Taylor said.
"If it gets branded for 'cosmetic usage' nobody's going to pay for it. We're hoping it's going to be looked at the same way as radical mastectomies for cancer patients. We think this should be considered in the same light," Taylor said. If tesamorelin is only approved for cosmetic purposes, that means patients could need to get a doctor's note saying their lipodystrophy is making them depressed.
Patient advocate Jules Levin also has some doubts. "I'm not extremely excited about the drug. It needs to be studied extensively. I wish patients would do exercise and diet more," said Levin. He said he wished more focus was put on increasing access to antiretrovirals, or developing treatments for African-Americans.
The FDA was supposed to conduct an advisory hearing on February 24, but recently announced the meeting will be postponed until May 29 for procedural reasons. Horn retains an optimistic stance.
"To say this is a drug to make people look beautiful misses the point. This is someone who's had something taken from them from medications," said Horn. "It improves quality of life and mental health. It allows them to take HIV medication. I equate this to women who have had breast reconstruction after mastectomies. I think it helps the emotional healing process."
Housing Works does not manufacture, endorse, promote, or sell any specific drug or therapy for any medical condition Consult with your Housing Works health care provider or another qualified professional who knows your specific medical history before making any treatment decisions. This information is intended for educational purposes only.